Page 30 - FLIPBOOK
P. 30
Degarelix is associated with lower all-cause mortality rates and CV events as
compared with GnRH agonists
A total of 2,632 patients were included in the meta-analysis, 986 patients received an LHRH agonist (leuprorelin or goserelin) and 1,646 patients
received degarelix® 1
▪ Cardiovascular events were less frequent in the FIRMAGON® group vs the LHRH agonist group (RR: 0.52, 95% CI: 0.34– 0.80, p = 0.003)
▪ The probability of overall survival at 1 year was significantly higher for patients treated with FIRMAGON® vs LHRH agonists (RR: 0.48, 95% CI:
0.26–0.90, p = 0.02)
CI; confidence interval; CV: cardiovascular; LHRH, luteinising hormone-releasing hormone; OS, overall survival; RR, risk
reduction.
Abufaraj VM et al. Eur Urol. 2021;79(1):44–53.
